-
Heart Failure Clinics Jan 2020Understanding the role of sex- and gender-related factors, when dealing with a global growing epidemic such as heart failure, is a much needed and unmet goal for health... (Review)
Review
Understanding the role of sex- and gender-related factors, when dealing with a global growing epidemic such as heart failure, is a much needed and unmet goal for health care providers and scientists in order to design targeted strategies, aimed at improving both clinical and patient reported outcomes measures in women and men with heart failure. The present review provides an overview of the current available evidence on sex- and gender-related differences in heart failure.
Topics: Global Health; Heart Failure; Humans; Morbidity; Sex Distribution; Sex Factors; Survival Rate
PubMed: 31735310
DOI: 10.1016/j.hfc.2019.08.005 -
The Journal of Oral Implantology Aug 2022
Topics: Dental Implants; Dental Prosthesis, Implant-Supported; Dental Restoration Failure; Survival Rate; Tooth
PubMed: 36054134
DOI: 10.1563/aaid-joi-D-22-Editorial.4804 -
Annals of Medicine Dec 2022Hidradenocarcinoma is a rare malignancy of sweat gland differentiation. Published literature has reported that hidradenocarcinoma has a high recurrence and metastasis... (Observational Study)
Observational Study
BACKGROUND
Hidradenocarcinoma is a rare malignancy of sweat gland differentiation. Published literature has reported that hidradenocarcinoma has a high recurrence and metastasis rate, and the prognosis is extremely poor. However, the sample sizes included in these studies are insufficient, and therefore, the findings are doubtful.
MATERIALS AND METHODS
Clinicopathological characteristics and survival data of 289 hidradenocarcinoma patients were extracted from the SEER database (covering 18 registries, 2000-2018) released in July 2021. The distribution of clinicopathological characteristics was compared using the Pearson chi-square test. Overall survival (OS) and cancer-specific survival (CSS) were analysed using the log-rank test and univariate analysis.
RESULTS
The primary site of hidradenocarcinoma in 121 patients was located in the head and neck, accounting for 41.9%, and the others were located in the trunk and limbs. For hidradenocarcinoma, the mean OS and CSS were 164 months and 165.9 months, respectively; the 10-year OS rate and CSS rate were 60.2% and 90.5%, respectively. Survival analysis showed that the primary site, sex, age, race, histologic grade, stage, and surgery are not associated with hidradenocarcinoma patients' OS or CSS. For head and neck hidradenocarcinoma or trunk and limbs hidradenocarcinoma, sex, age, race, histologic grade, AJCC stage, and primary site surgery are still not related to prognosis. Tumour size is correlated with patients' OS rather than CSS.
CONCLUSIONS
Hidradenocarcinoma is a malignant tumour with a good prognosis, which is different from previous views. Tumour size is inversely proportional to patients' overall survival time affecting the OS and CSS of patients. Improving health awareness, initial histological examination and timely surgery are the keys to improving the prognosis.
Topics: Humans; Prognosis; SEER Program; Survival Analysis; Survival Rate
PubMed: 35107407
DOI: 10.1080/07853890.2022.2032313 -
Zhongguo Dang Dai Er Ke Za Zhi =... Aug 2021To study the survival rate and the incidence of complications of very preterm infants and the factors influencing the survival rate and the incidence of complications.
OBJECTIVES
To study the survival rate and the incidence of complications of very preterm infants and the factors influencing the survival rate and the incidence of complications.
METHODS
The medical data of the very preterm infants with a gestational age of <32 weeks and who were admitted to the Department of Neonatology in 11 hospitals of Jiangsu Province in China from January 2018 to December 2019 were retrospectively reviewed. Their survival rate and the incidence of serious complications were analyzed. A multivariate logistic regression analysis was used to evaluate the risk factors for death and serious complications in very preterm infants.
RESULTS
A total of 2 339 very preterm infants were enrolled, among whom 2 010 (85.93%) survived and 1 507 (64.43%) survived without serious complications. The groups with a gestational age of 22-25 weeks, 2626 weeks, 27-27 weeks, 2828 weeks, 2929 weeks, 3030 weeks, and 31-31 weeks had a survival rate of 32.5%, 60.6%, 68.0%, 82.9%, 90.1%, 92.3%, and 94.8% respectively. The survival rate tended to increase with the gestational age (<0.05) and the survival rate without serious complications in each gestational age group was 7.5%, 18.1%, 34.5%, 52.2%, 66.7%, 75.7%, and 81.8% respectively, suggesting that the survival rate without serious complications increased with the gestational age (<0.05). The multivariate logistic regression analysis showed that high gestational age, high birth weight, and prenatal use of glucocorticoids were protective factors against death in very preterm infants (<0.05), and 1-minute Apgar score ≤3 was a risk factor for death in very preterm infants (<0.05); high gestational age and high birth weight were protective factors against serious complications in very preterm infants who survived (<0.05), while 5-minute Apgar score ≤3 and maternal chorioamnionitis were risk factors for serious complications in very preterm infants who survived (<0.05).
CONCLUSIONS
The survival rate is closely associated with gestational age in very preterm infants. A low 1-minute Apgar score (≤3) may increase the risk of death in very preterm infants, while high gestational age, high birth weight, and prenatal use of glucocorticoids are associated with the reduced risk of death. A low 5-minute Apgar score (≤3) and maternal chorioamnionitis may increase the risk of serious complications in these infants, while high gestational age and high birth weight may reduce the risk of serious complications.
Topics: Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Pregnancy; Retrospective Studies; Survival Rate
PubMed: 34511171
DOI: 10.7499/j.issn.1008-8830.2102037 -
Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study.Endocrine Nov 2023Overall, thyroid cancer is the most common endocrine malignancy. This cancer is fifth most common cancer among adult women and the second most common cancer in women... (Meta-Analysis)
Meta-Analysis
PURPOSE
Overall, thyroid cancer is the most common endocrine malignancy. This cancer is fifth most common cancer among adult women and the second most common cancer in women over 50 years old and it occurs in women 3 times more than men. The present systematic review and meta-analysis were designed with the aim of determining the 5-year survival rate of thyroid cancer in Asian countries in 2022.
METHODS
The current study is a systematic review and meta-analysis of thyroid cancer survival rates in Asian countries. Researchers in the study searched for articles published in six international databases: PubMed/Medline, EMBASE, Scopus, Google Scholar, ISI (Web of Knowledge), and ProQuest until July 03, 2022. A checklist (The Newcastle-Ottawa Quality Assessment Form) has been prepared in previous studies to evaluate the quality of articles.
RESULTS
In general, 38 articles were entered for the meta-analysis. The 5-year survival rate was 95.3%, with a 95% confidence interval of 93.5% to 96.6%. The year of study is a cause of variability in results of 5-year (Reg Coef = 0.145, P < 0.001). According to the results, an increased survival rate across the study period was observed. Human Development Index was a cause of variability in results of 5-year survival rates (Reg Coef = 12.420, P < 0.001). The results of Table 2 showed that women have 4% more 5-year survival rate than men (Hazard ratio: 1.05 CI: 95% 1.04-1.06)).
CONCLUSION
In general, the 5-year survival of thyroid cancer in Asian countries was higher than in European countries, but it is at a lower level than in the United States.
Topics: Male; Adult; Humans; Female; Middle Aged; Survival Rate; Thyroid Neoplasms; Asia; Endocrine Gland Neoplasms; Europe
PubMed: 37269425
DOI: 10.1007/s12020-023-03408-5 -
Best Practice & Research. Clinical... Mar 2021The past three years have witnessed remarkable progress in acute myeloid leukemia (AML). The approval and development of targeted therapies and novel agents has improved... (Review)
Review
The past three years have witnessed remarkable progress in acute myeloid leukemia (AML). The approval and development of targeted therapies and novel agents has improved outcomes for patients with traditionally poor survival rates. This review has summarized the survival impact of chemotherapy-based regimens in AML and described recent advances that will be of significance in the near future.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Survival Rate
PubMed: 33762103
DOI: 10.1016/j.beha.2021.101248 -
Clinical Oncology (Royal College of... Sep 2021Modern multimodality cancer treatment has led to a rise in cancer survivors, and by 2030 the survival rate is estimated to increase by 31.4%. This is an impressive... (Review)
Review
Modern multimodality cancer treatment has led to a rise in cancer survivors, and by 2030 the survival rate is estimated to increase by 31.4%. This is an impressive survival statistic on which clinicians and services continue to build. One of the less well-acknowledged consequences of survivorship among health professionals and patients alike is female sexual dysfunction, despite it occurring in more than 60% of women diagnosed with cancer. The systematic assessment and management of late effects from cancer lack integration within current models of oncology follow-up. Although highly prevalent, issues linked to sexual health are often not addressed among survivors. This overview aims to focus on the sexual impact of gynaecological cancer treatment. Clinicians should raise the topic of the sexual consequences of cancer treatment as a legitimate aspect of survivorship and service provision. Increased focus on the sexual consequences of treatment and cancer survivorship may in time lead to greater clinical recognition, service development and, most importantly, increase research focused on the effective management of what remains a neglected aspect of cancer care.
Topics: Cancer Survivors; Female; Genital Neoplasms, Female; Humans; Sexual Behavior; Survival Rate; Survivors
PubMed: 34281725
DOI: 10.1016/j.clon.2021.07.003 -
Acta Medica Indonesiana Jan 2022The incidence of osteosarcoma reached 16.8 cases annually at dr. Cipto Mangunkusumo Hospital in 1995-2008. Previous studies suggested that prolonged neoadjuvant... (Review)
Review
BACKGROUND
The incidence of osteosarcoma reached 16.8 cases annually at dr. Cipto Mangunkusumo Hospital in 1995-2008. Previous studies suggested that prolonged neoadjuvant chemotherapy followed by delayed surgery improves the clinical outcome. Prolonged neoadjuvant chemotherapy followed by delayed surgery commonly occurs in Indonesia, as diagnostic imaging and surgery waiting list will delay the surgery. The aim of this study is to observe the survival rate and the event-free survival rate of osteosarcoma patients with prolonged neoadjuvant chemotherapy and delayed surgery.
METHODS
This review included randomized controlled trials (RCTs), cohort studies, retrospective cohort studies, clinical trials, and reviews. Literature search was conducted through MEDLINE (PubMed search engine), Cochrane Central Register of Controlled Trial, and Scopus. The studies were screened and selected according to inclusion criteria by author and contributors independently.
RESULTS
Six studies were included in the qualitative synthesis of this study. Overall survival rate, event-free survival rate, histological response and recurrence as well as neoadjuvant chemotherapy duration, cycle and regiment were assessed in this study.
CONCLUSION
Prolonged neoadjuvant chemotherapy and delayed surgery results in 5-years survival rate of 43.2% to 96.6% and 5-years event-free survival rate of 35.7% to 86.4%.
Topics: Bone Neoplasms; Humans; Indonesia; Neoadjuvant Therapy; Osteosarcoma; Survival Rate
PubMed: 35398837
DOI: No ID Found -
Medicina (Kaunas, Lithuania) Oct 2022: The purpose of this study is to observe the usefulness of autogenous tooth transplantation by examining the cumulative survival rate according to the period of...
: The purpose of this study is to observe the usefulness of autogenous tooth transplantation by examining the cumulative survival rate according to the period of auto-transplanted teeth as pre-implant treatment. : This study was conducted on 111 patients who visited Kyungpook National University Dental Hospital and underwent autogenous tooth transplantation between November 2008 and January 2021 (about 13 years). The cumulative survival rate of autogenous tooth transplantation according to the causes of extraction of the recipient tooth (caries, periapical lesion, crack, crown fracture, periodontitis) and condition of opposing teeth (natural teeth vs. fixed prosthesis). The cumulative survival rate of autogenous tooth transplantation according to the age (under 30 vs. over 30) was also investigated and it was examined whether there were any differences in each factor. : The average follow-up period was 12 months, followed by a maximum of 162 months. The 24-month cumulative survival rate of all auto-transplanted teeth was 91.7%, 83.1% at 60 months and the 162-month cumulative survival rate was 30.1%. There were no statistical differences between the causes of extraction of the recipient's teeth, differences in the condition of the opposing teeth, and differences under and over the age of 30. : The survival rate of autogenous tooth transplantation appears to be influenced by the conditions of the donor tooth rather than the conditions of the recipient tooth. Although autogenous tooth transplantation cannot completely replace implant treatment, it is meaningful in that it can slightly delay or at least earn the time until implant placement is possible.
Topics: Humans; Survival Rate; Tooth; Transplantation, Autologous; Tooth Extraction; Tooth Fractures; Follow-Up Studies; Treatment Outcome
PubMed: 36363473
DOI: 10.3390/medicina58111517 -
Air Medical Journal 2024Drawing from a comprehensive Japan-based literature review and the author's personal experience, this article presents findings that highlight potential improvements in... (Review)
Review
Drawing from a comprehensive Japan-based literature review and the author's personal experience, this article presents findings that highlight potential improvements in clinical outcomes, such as reduced mortality rates, by optimizing the current resuscitation procedure for cardiopulmonary arrest. Many countries have adopted similar procedures for cardiopulmonary arrest. This article presents a prioritized resuscitation method based on scientific evidence, aiming to improve survival rates. The study, which was conducted in Japan, revealed inconsistencies in the current resuscitation procedure for cardiopulmonary arrest. The study did not involve direct participants but relied on literature review for data collection. A literature review was conducted to analyze the survival rates of various resuscitation methods. The interventions reviewed in the literature included cardiopulmonary resuscitation, automated external defibrillator, and automatic mechanical chest compressions. The survival rate of cardiopulmonary arrest in Japan was found to be low. The results of the literature review suggest that cardiopulmonary resuscitation or automatic mechanical chest compressions should be applied before using an automated external defibrillator. The study emphasizes the need to prioritize resuscitation methods with higher survival rates. This article presents a prioritized resuscitation method based on scientific evidence, aiming to improve survival rates. It is hoped that this new approach will lead to a significant improvement in the survival rates of cardiopulmonary arrest patients.
Topics: Humans; Cardiopulmonary Resuscitation; Japan; Heart Arrest; Defibrillators; Survival Rate; Out-of-Hospital Cardiac Arrest
PubMed: 38821711
DOI: 10.1016/j.amj.2023.12.003